Alcami Corporation is upgrading its Tennessee pharmaceutical manufacturing facility to standardize quality systems and expand packaging capacity, according to a June 22, 2026, company announcement. The project includes integrating the site into Alcami’s enterprise-wide Quality Management System (QMS), upgrading packaging lines with serialization capabilities, and expanding temperature-controlled storage infrastructure to support growing client demand.
How are CDMOs standardizing global manufacturing quality?
Contract Development and Manufacturing Organizations (CDMOs) are increasingly adopting unified digital platforms to ensure operational consistency across acquired sites. Alcami is shifting its Tennessee facility—gained through the acquisition of Tjoapack—to the MasterControl digital QMS platform, already in use across the company’s broader U.S. network. According to Alcami, this transition aims to improve regulatory compliance and provide real-time visibility into operations. Standardizing systems across multiple locations allows firms to reduce the administrative burden of managing disparate quality protocols while minimizing the risk of audit findings.
Why is serialization becoming a priority for packaging lines?
Regulatory bodies worldwide are mandating serialization to track and trace pharmaceutical products, forcing manufacturers to modernize aging infrastructure. Alcami plans to install new equipment and increase line speeds at its Tennessee plant to accommodate these requirements. By embedding serialization early in the packaging process, manufacturers can prevent counterfeit drugs from entering the supply chain and meet stringent requirements from the FDA and international health authorities. This shift reflects a broader industry trend where packaging is no longer a secondary service but a highly technical, regulated component of the drug development lifecycle.
What role does high-density storage play in supply chain continuity?
Expanding temperature-controlled capacity is a strategic hedge against supply chain volatility. Alcami is incorporating its Tennessee site into a broader GMP storage network that includes high-density storage and improved warehousing redundancy. According to Interim CEO Patrick Walsh, these upgrades are designed to enhance continuity of supply. By centralizing storage capabilities, companies can maintain the stability of biologics and sensitive compounds, even when faced with logistics disruptions. This infrastructure-first approach allows firms to offer “end-to-end” support, keeping products within the same quality-controlled network from primary manufacturing to final distribution.
Did you know?
The global CDMO market is experiencing significant consolidation. Firms like Alcami, backed by private equity groups including GHO Capital and The Vistria Group, use these investments to scale operations rapidly, allowing them to compete with larger, multinational pharmaceutical manufacturers.
Frequently Asked Questions
- What is a CDMO? A Contract Development and Manufacturing Organization provides outsourced services to the pharmaceutical industry, ranging from drug discovery and clinical trials to commercial-scale manufacturing and packaging.
- Why is QMS standardization important? It ensures that every product manufactured at any site meets the same quality benchmarks, which simplifies regulatory filings and reduces the likelihood of product recalls.
- When will the new packaging capacity be available? Alcami expects its new high-speed bottle packaging line at the Tennessee facility to be operational by the first half of 2027.
Interested in the latest shifts in pharmaceutical manufacturing? Subscribe to our weekly newsletter for updates on industry consolidation and infrastructure trends.